Adaptimmune
Adaptimmune receives US FDA Accelerated Approval for engineered cell therapy for a solid tumour
August 2, 2024Medical Communications Adaptimmune, Oncology, accelerated approval, engineered cell therapy, oncology, synovial sarcoma
Adaptimmune Therapeutics has announced today that the US Food and Drug Administration (FDA) has given accelerated approval for TECELRA (afamitresgene …
Bad news for Adaptimmune as partial clinical hold placed on T-cell oncology trial
August 4, 2016Research and Development Adaptimmune, T cell, oncology, t-cell
Adaptimmune Therapeutics has received notice from the US Food and Drug Administration (FDA) that a partial clinical hold has been …
GSK and Adaptimmune expand R&D collaboration
February 3, 2016Research and Development Adaptimmune, GSK, T-cell therapy, immunotherapy, liposarcoma, rare cancer, sarcoma
Adaptimmune Therapeutics and GlaxoSmithKline have expanded the terms of their strategic collaboration agreement, to run clinical trials of Adaptimmune’s potential …
Adaptimmune makes executive hires from GSK
March 5, 2015Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Adaptimmune, Adrian Rawcliffe, Rafael Amado
UK and US clinical-stage biotech firm Adaptimmune has increased its senior team with the appointment of Dr Rafael Amado as …
Adaptimmune board changes amid funding boost
September 29, 2014Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Adaptimmune, Ali Behbahani, Elliott Sigal, Peter Thompson, david mott
Oxford-based biotech firm Adaptimmune has secured some significant financial support whilst also making changes to its board. David Mott (pictured), …
GSK signs Adaptimmune deal
June 3, 2014Manufacturing and Production, Research and Development, Sales and Marketing AZ, Adaptimmune, BMS, Cancer, GSK, oncology
GlaxoSmithKline has signed a deal to develop and commercialise biotech firm Adaptimmune’s lead clinical cancer programme with T-cell receptors (TCRs), …
Immunocore chief executive cements role at Adaptimmune
March 27, 2014Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Adaptimmune, immunocore, noble
Biotech firm Adaptimmune has confirmed the full-time appointment of James Noble as its chief executive. Noble has been chief executive …
Adaptimmune wins fund payout
March 26, 2014Research and Development, Sales and Marketing Adaptimmune, Cancer, T cell, biomedical, noble, sme
Biotech firm Adaptimmune has been awarded £2.1 million from the UK government’s Biomedical Catalyst Fund, which was set up to …
Working Life: Adaptimmune’s Helen Tayton-Martin
October 31, 2011Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Adaptimmune, Working Life
Helen Tayton-Martin who is an executive director at Adaptimmune, talks to Pharmafocus about her role and working in cell therapy. …
